IGC Pharma (IGC) Notes Payables (2011 - 2026)

IGC Pharma (IGC) posted quarterly Notes Payables of $27000.0 for Q1 2026, up 800.0% quarter-over-quarter from $3000.0 in Q2 2022.

IGC Pharma (IGC) Notes Payables (2011 - 2026) Analysis & Trends

IGC Pharma (IGC) has reported Notes Payables for 12 consecutive years, with $27000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Notes Payables changed N/A year-over-year to $27000.0; the TTM figure through Mar 2026 stood at $27000.0 (changed N/A YoY), while the FY2026 annual figure was $27000.0, changed N/A from the prior year.
Notes Payables climbed to $27000.0 in Q1 2026 per IGC's latest filing, from $3000.0 in the prior quarter.
Across five years, Notes Payables topped out at $27000.0 in Q1 2026 and bottomed at $3000.0 in Q1 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	IGC Pharma	27.20 Mn	26.94 Mn	-

Download Data